180 related articles for article (PubMed ID: 33378592)
1. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma.
Chaudhary R; Slebos RJC; Song F; McCleary-Sharpe KP; Masannat J; Tan AC; Wang X; Amaladas N; Wu W; Hall GE; Conejo-Garcia JR; Hernandez-Prera JC; Chung CH
Mol Carcinog; 2021 Feb; 60(2):138-150. PubMed ID: 33378592
[TBL] [Abstract][Full Text] [Related]
2. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
[TBL] [Abstract][Full Text] [Related]
3. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
Zeng L; Beggs RR; Cooper TS; Weaver AN; Yang ES
Mol Cancer Ther; 2017 Apr; 16(4):591-600. PubMed ID: 28138028
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
5. CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model.
Campagne O; Davis A; Maharaj AR; Zhong B; Stripay J; Farmer D; Roussel MF; Stewart CF
Eur J Pharm Sci; 2020 Jan; 142():105106. PubMed ID: 31669383
[TBL] [Abstract][Full Text] [Related]
6. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
[TBL] [Abstract][Full Text] [Related]
7. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF
Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495
[No Abstract] [Full Text] [Related]
8. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
Hong DS; Moore K; Patel M; Grant SC; Burris HA; William WN; Jones S; Meric-Bernstam F; Infante J; Golden L; Zhang W; Martinez R; Wijayawardana S; Beckmann R; Lin AB; Eng C; Bendell J
Clin Cancer Res; 2018 Jul; 24(14):3263-3272. PubMed ID: 29643063
[No Abstract] [Full Text] [Related]
10. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
Ruicci KM; Meens J; Sun RX; Rizzo G; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Boutros PC; Ailles L; Nichols AC
Int J Cancer; 2019 Oct; 145(8):2100-2106. PubMed ID: 30468243
[TBL] [Abstract][Full Text] [Related]
11. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
12. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
13. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
14. Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Ghelli Luserna Di Rorà A; Iacobucci I; Imbrogno E; Papayannidis C; Derenzini E; Ferrari A; Guadagnuolo V; Robustelli V; Parisi S; Sartor C; Abbenante MC; Paolini S; Martinelli G
Oncotarget; 2016 Aug; 7(33):53377-53391. PubMed ID: 27438145
[TBL] [Abstract][Full Text] [Related]
15. Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma.
Ohashi S; Kikuchi O; Nakai Y; Ida T; Saito T; Kondo Y; Yamamoto Y; Mitani Y; Nguyen Vu TH; Fukuyama K; Tsukihara H; Suzuki N; Muto M
Mol Cancer Ther; 2020 Jun; 19(6):1363-1372. PubMed ID: 32371587
[TBL] [Abstract][Full Text] [Related]
16. Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development.
Angius G; Tomao S; Stati V; Vici P; Bianco V; Tomao F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):9-20. PubMed ID: 31512029
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
19. Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib.
Heidler CL; Roth EK; Thiemann M; Blattmann C; Perez RL; Huber PE; Kovac M; Amthor B; Neu-Yilik G; Kulozik AE
Int J Cancer; 2020 Aug; 147(4):1059-1070. PubMed ID: 31782150
[TBL] [Abstract][Full Text] [Related]
20. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
